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Pre-eclampsia is a life threatening complication of pregnancy which contributes to
maternal and perinatal morbidity and mortality.
1 The exact pathogenesis of pre-
eclampsia remains unclear. It has been suggested that endothelial dysfunction
may play a central role in the development of pre-eclampsia. Impaired tropho-
blastic invasion of the maternal placental bed is considered to be the initial event
of endothelial dysfunction in pre-eclampsia. Uterine artery Doppler abnormalities
are suggestive of increased impedance to blood flow in the uterine circulation
2 as
well as a failure of physiologic transformation of the spiral arteries diagnosed by
examination of placental bed biopsies.
3 Consequently, reduction of uteroplacental
blood perfusion by shallow implantation results in local placental hypoxia. A
hypoxic/ischemic placenta may then release placental factors into maternal
circulation eventually causing endothelial dysfunction, which leads to the main
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Purpose: There is a paucity of information on the serum soluble vascular endothelial growth factor receptor-2
(sVEGFR-2) concentrations, membranous VEGFR-2 expression and the mechanism involved in their modulations
during the clinical onset of pre-eclampsia. This cross-sectional study was conducted to evaluate the concentration of
sVEGFR-2 in serum and to investigate the expression of membranous VEGFR-2 in placentae of pre-eclampsia
group. Materials and Methods: The serum levels of sVEGFR-2 (n = 120) and the expression of membranous
VEGFR-2 in placentae (n = 100) were analysed at third trimester of pregnancy by enzyme linked immunosorbent
assay (ELISA) and immunohistochemistry respectively. The diagnostic parameters of sensitivity, specificity and
association of soluble and membranous VEGFR-2 in these patients were evaluated. Results: The serum levels of
sVEGFR-2 in pre-eclampsia patients were found to be significantly reduced (p = 0.01, p = 0.001) in early and late
pre-eclamptic sub-groups as compared to their respective third trimester control sub-groups. Also, the receiver
operating characteristic (ROC) curve analysis showed a cut-off value of 7350.4 pg/mL, higher sensitivity (76%)
and specificity (76%) for sVEGFR-2 in late onset (> 34 weeks) pre-eclamptic group. Significant down-regulation
of membranous VEGFR-2 immunoreactivity was observed in all the placental cells (p = 0.0001) at > 34 weeks pre-
eclamptic group. Conclusion: The reduced serum levels of soluble VEGFR-2 and the down-regulated expression
of membranous VEGFR-2 in the study group denoted abnormality in VEGF mediated placental function in all
placental cells and thus VEGFR-2 may be a key factor, intimately associated with pre-eclampsia. This study shows
the clinical utility of soluble and membranous VEGFR-2 in pre-eclampsia patients.
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interest.clinical symptoms of pre-eclampsia. The identification of
circulating factors that mediate endothelial dysfunction has
been of great research interest for decades. Vascular
endothelial growth factor (VEGF) is necessary to maintain
normal endothelial health in the adult vasculature, which
extends beyond angiogenesis. VEGF is a dimeric glyco-
protein with potent angiogenic properties and promotes
endothelial cell proliferation, migration and survival and
exerts biologic effects through two high-affinity tyrosine
kinase receptors i.e. Vascular endothelial growth factor
receptor-1 (VEGFR-1) / fms-like tyrosine kinase-1 (flt-1)
and Vascular endothelial growth factor receptor-2 / kinase
insert domain containing receptor (KDR) / fetal liver
kinase-1 (Flk-1). VEGFR-1 is considered to be a ‘decoy’
receptor and VEGFR-2, the major mediator of the mito-
genic, angiogenic, permeability enhancing
4 and endothelial
survival effects of VEGF. Both VEGFR-1 and VEGFR-2
have two isoforms: a membranous isoform and a soluble
isoform.
Both receptors share common features such as seven
immunglobulin-like extracellular domains, a single trans-
membrane region and a consensus tyrosine kinase se-
quence interrupted by a kinase insert domain, and are
highly glycosylated.
5,6 Although VEGFR-1 binds to VEGF
with substantially higher affinity, most of the biological
effects of VEGF seem to be mediated via VEGFR-2.
7
The effect of blockage of VEGF action on the pathophy-
siology of pre-eclampsia has been suggested recently by
several studies in both animals and humans. Admini-
stration of anti-VEGF compounds can induce hypertension
and proteinuria in non-pregnant animals
8 and humans
enrolled in anti angiogenic trials.
9 Furthermore, anti-VEGF
therapy in patients with cancer has been associated with
hypertension, proteinuria and the reversible posterior
leukoencephalopathy syndrome, all of which are the
hallmarks of pre-eclampsia and eclampsia.
10,11
Accumulating evidence suggests that a balance among
VEGF, placental growth factor (PLGF) and their receptors is
important for effective vasculogenesis, angiogenesis and
placental development during pregnancy. In our previous
study on pre-eclampsia, a significant up-regulation of soluble
and membranous VEGFR-1 was observed.
12 Recently,
sVEGFR-2 has been detected in human plasma.
13 The
recombinant form of this protein has anti-angiogenic
activity.
14 Plasma sVEGFR-2 concentrations are lower in
patients with systemic lupus erythematosus disease
15 and
higher in those with acute leukemia, compared to healthy
controls.
16 There is a paucity of information on serum
sVEGFR-2 concentrations, placental VEGFR-2 expression,
and the mechanisms involved in their modulations before
and during the clinical onset of pre-eclampsia.
17 Therefore, a
cross-sectional study was undertaken to appraise the serum
soluble VEGFR-2 concentration as well as placental
membranous VEGFR-2 changes in pre-eclampsia and their
coalition with the disease. 
One hundred and twenty volunteers for this cross-sectional
study were recruited from the out patient department (OPD)
clinic between the years 2004 to 2006 from the Department
of Obstetrics and Gynaecology, Safdarjang Hospital, after
obtaining written consent from patients. The Research and
Ethics Committee of Vardhman Mahavir Medical College
and Safdarjang Hospital (New Delhi, India) approved the
study. Pre-eclampsia was defined as diastolic blood
pressure above 90 mmHg and systolic blood pressure
above 140 mmHg in at least two consecutive measure-
ments, six hours apart, oedema and proteinuria ≥ 300 mg in
a 24 hour urine collection or ≥ 1+ dipstick on a random
urine sample. Patients with a history of hyperten-sion, or
any renal disease pre-eclampsia were excluded from the
study. Healthy pregnant women with uncompli-cated
pregnancies without any history of chronic medical illness
served as the control group. All the subjects were classified
and numbered subsequently before any laboratory analysis
to avoid bias in results.
A total of 120 serum samples were collected, of which
20 were from non-pregnant women, and 50 from third
trimester pre-eclampsia patients were compared with 50
gestationally matched uncomplicated pregnant women
(control group). Blood samples from pre-eclampsia
patients were collected after the manifestation of disease.
The samples from control group were matched with study
groups by gestational weeks. Serum was separated by
centrifugation and stored at -80˚C till analysed.
One hundred placentae were collected from patients of
normotensive third trimester control group (n = 50) and
pre-eclampsia group (n = 50). Tissues were randomly
sampled from each placenta and were immersion-fixed in
10% formalin and embedded in paraffin.
All the tissue and serum samples were sub-classified as
either early pre-eclampsia (≤ 34 weeks) or late pre-
eclampsia (> 34 weeks) disease, as well as gestationally
matched preterm (≤ 34 weeks) and term (> 34 weeks)
control group according to the gestational age.
ELISA
Serum levels of sVEGFR-2 in all the samples were quanti-
fied by enzyme linked immunosorbent assay (ELISA;
Quantikine human soluble VEGFR-2, R & D Systems
Europe Ltd, Barton Lane, Abingdon Science Park, Abing-
don, United Kingdom). All assays were performed in
VEGFR-2 in Pre-Eclampsia
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MATERIALS AND METHODSrespective duplicate samples. ELISA employs a quantita-
tive sandwich immunoassay technique. Briefly, recombinant
human VEGFR-2 standards and maternal plasma specimens
were incubated in duplicate wells of the microtiter plates
pre-coated with monoclonal antibodies specific for
VEGFR-2. After an incubation period, the assay plates were
subjected to a wash step to remove unbound antibody-
enzyme reagent. Then, an enzyme-linked polyclonal
antibody specific to VEGFR-2 was added to the wells.
Following a wash to remove any unbound antibody-enzyme
reagent, a substrate solution (tetramethyl-benzidine) was
added to the wells. Colour developed in the assay plates,
proportionally to the amount of VEGFR-2 bound in the
initial step. The optical density was determined by
subtracting readings at 540 nm from readings at 450 nm.
The protein levels were calculated using a standard curve
derived from a known concentration of respective recombi-
nant proteins. The minimum detection dose of assays was
3.5 pg/mL. The inter and intra-assay coefficients of varia-
tion were 6.5% and 3.5%, respectively. The sensitivity of
the assay was 4.6 pg/mL. Assays were performed by
personnel who were unaware of the outcome of the pre-
gnancy. Samples were randomly ordered for analysis.
Immunohistochemistry
Serial sections of each tertiary villi of placental tissue were
collected on poly-L-lysine coated slides (Sigma, St. Louis,
MO, USA), dewaxed, and dehydrated, and antigen retrieval
treatment was carried out in a water bath at 100˚C for 20
minutes. After washing in 0.01M Tris buffered saline (pH-
7.4), sections were then incubated with primary mono-
clonal anti-human anti body of VEGFR-2 (Flk-1, A-3, sc-
6251, Santa Cruz Biotechnology, Inc., Delaware Avenue,
Santa Cruz, USA) at a dilution of 1 : 100 and incubated at
4˚C. Sections were then washed with 0.05% Tween-20 in
0.01M TBS. The sections were incubated in secondary
antibody for 45 minutes at room temperature, followed by
incubation with biotinylated link antibody and peroxidase-
labelled streptavidin for 45 minutes (LSAB + System-
HRP, Dako Cytomation, Glostrup, Denmark). Staining
was completed after incubation with substrate-chromogen
solution (liquid DAB, Dako, Code: K0679) and was
applied until the maximum level of reaction product was
obtained. Sections were then counter-stained with Mayer’s
haematoxylin solution and mounted with disterene dibutyl
phthalate xylene (DPX). Negative control stainings were
performed using IgG non-immune serum (Dako) in all the
slides and for positive control; rabbit anti-human chorio-
gonadotropin(hCG, A-023102, Dako, Denmark) was used
to identify trophoblast, endothelial and Hofbauer cells.
Photomicrographs were taken under an Olympus micro-
scope [(model BX-51) Olympus America, Inc, Melville,
NY, USA)], and the images were captured by charge
coupled device (CCD) camera and an “Olysia Bio-report”
software-linked personal computer. Tissue sections were
evaluated for protein localization and intensity. The intensity
of immunoreactivity was semi-quantitatively evaluated as
follows.
Positively stained cells were grouped according to the
following categories: (no staining), +1 (weak, but detectable),
+2 (moderate), +3 (intense). In each slide, five different
areas were evaluated under a microscope using 400×
original magnification. For each tissue, an H-score value
was calculated by adding the percentage of cells grouped
in one intensity category and multiplying this number with
the weighed intensity of the staining, using the formula
Hscore = Pc (s + 1), where s represents the intensity scores
and Pc is the corresponding percentage of the cells. In each
slide, five different areas were evaluated under a micro-
scope using 400× magnification.
18 All tissues were exa-
mined by three observers who were blinded to the slides
(i.e. patient’s identity, clinical details and gestational ages). 
Statistical analysis 
Statistical analysis was performed using statistical software
STATA 9.0 (College station, Texas, USA). Data were
presented as number (%), and mean ± SD as the require-
ment. The difference in means among the groups was
compared using Mann-Whitney test / One Way ANOVA /
Kruskal-Wallis test with Bonferroni correction. 
The receiver operating characteristic (ROC) curve ana-
lysis was also performed to identify the cut-off of serum
levels for pre-eclamptic patients in comparison to normal
subjects. The p value < 0.05 was considered statistically
significant.
There were no significant differences in maternal age, baby
weight, and placental weight between the control group and
in the pre-eclamptic group. At ≤34 weeks, the primigravidae
women were found to be 52% and 56% in control group and
pre-eclamptic group, respectively. However, at > 34 weeks,
the primigravidae women were found to be 48% and 60% in
the control group and in the pre-eclamptic group respe-
ctively. The difference in mean systolic blood pressure and
diastolic blood pressure was significant in the study group
than in the control group (Table 1). 
ELISA
The mean serum concentration of sVEGFR-2 in the
control group was significantly higher (p = 0.02) at > 34
weeks (8693.8 ± 2829.7 pg/mL) as compared to ≤ 34
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RESULTSweeks (7645.8 ± 1938.0 pg/mL) while the sVEGFR-2
concentrations in pre-eclampsia were found to be down-
regulated at > 34 weeks (Mean ± SD: 6266.6 ± 1824.2
pg/mL) as compared to ≤ 34 weeks (mean ± SD: 6541.6 ±
3285.8 pg/mL). Nevertheless, these levels were found to be
substantially lower and significant (p = 0.01, p = 0.001) in
pre-eclamptic sub-groups (≤ 34 and > 34 weeks) as
compared to their respective control groups (Table 2, Fig. 1).
VEGFR-2 in Pre-Eclampsia
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Table 1.Clinical Details of the Study Groups
≤34 wks > 34 wks
Parameters Control Pre-elampsia 
pvalue
Control Pre-elampsia
pvalue
(n = 25) (n = 25) (n = 25) (n = 25)
Maternal age
25.08 ± 2.94 24.8 ± 2.98 1.000 24.24 ± 2.48 23.08 ± 3.01 0.934
(yr, mean ± SD)
Primigravida
13 (52) 14 (56) - 12 (48) 15 (60) -
no. (%)
Systolic BP 
116.56 ± 4.41 144.08 ± 20.65 0.0001* 118.08 ± 7.07 147.84 ± 7.95 0.0001*
(mean ± SD)
Diastolic  BP  
73.28 ± 7.85 106.96 ± 11.35 0.0001* 78.48 ± 11.37 100 ± 8.00 0.0001*
(mean ± SD)
Baby wt (g)
1654 ± 429.61 1404.04 ± 535.30 0.383 2976.8 ± 278.45 2408 ± 583.39 0.0001*
(mean ± SD)
Placentae wt (g)
406.48 ± 49.07 410.28 ± 82.66 1.000 487.52 ± 80.99 443.6 ± 86.02 0.265
(mean ± SD)
BP, blood pressure, wt, weight.
*p< 0.05 is considered to be significant.
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Fig. 1.sVEGFR-2 concentrations (pg/mL) in maternal serum of control and pre-eclamptic patients. The median serum concentration of sVEGFR-2 was
significantly decreased in pre-eclmpsia patients. The horizontal lines indicate the mean values of the study groups. (A) In ≤34 weeks (p= 0.01).  (B) In
> 34 weeks (p= 0.001). sVEGFR-2, soluble vascular endothelial growth factor receptor-2 ; VEGFR-2, vascular endothelial growth factor receptor-2. 
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Table 2.Serum Concentration of sVEGFR-2 in Control and Preeclampsia Cases 
Gestational age
Control (n = 50) Pre-eclampsia (n = 50)
pvalue
(mean ± SD- pg/mL, range)  (Mean ± SD- pg/mL, range) 
≤34 wks
7645.8 ± 1938.0 6541.6 ± 3285.8 0.01
(5200.6 - 10572.9) (2025.8 - 18328.8)
> 34 wks
8693.8 ± 2829.7 6266.6 ± 1824.2 0.001
(3844.9 - 16486.7) (3462.01 - 10282.26)
VEGFR-2, vascular endothelial growth factor redeptor-2; sVEGFR-2, soluble vascular endothelial growth factor receptor-2. 
VEGFR-2 level of non-pregnant group (n = 20), 8497.6 ± 2968.8, p= 0.85  (mean ± SD).
Total sVEGFR-2 level of control group was 7617.74 ± 3223.6.
Total sVEGFR-2 level of Pre-eclamptic  group was 6956.2 ± 1988.
p< 0.05 is considered to be significant.Therefore, there was an inverse association between the
serum concentrations of sVEGFR-2 in control and pre-
eclampsia group as the gestation advances (Table 2). There
was no significant difference in the mean serum concen-
tration of sVEGFR-2 between the non-pregnant women
(mean ± SD: 8497.6 ± 2968.8 pg/mL) and the women
with normal pregnancy (p = 0.85, Table 2).
According to the ROC curve analysis (Fig. 2), the serum
sVEGFR-2 level in pre-eclampsia in early onset (≤ 34
weeks) had the sensitivity and specificity of 60% and area
under curve (AUC = 0.69). However, we observed the
sensitivity and specificity of 76% and AUC = 0.79 in the
late onset of disease (> 34 weeks). Serum sVEGFR-2 had
the highest positive likelihood ratio (LR - 1.5) women with
pre-eclampsia at ≤ 34 weeks and at > 34 weeks highest
positive LR is 3.1 (Table 3). 
Immunohistochemistry
At ≤ 34 weeks, in the control group as well as in the pre-
eclampsia group, moderate membranous VEGFR-2 immu-
noreactivity was observed in the cells (sycytiotrophoblast,
cytotrophoblast, endothelial and Hofbauer) of tertiary villi
of placenta as shown in Figs. 3C, D.
At > 34 weeks, in control group, as the pregnancy pro-
gressed, the intensity of VEGFR-2 immunoreactivity was
found to increase as compared to ≤ 34 weeks control pla-
centae in all cells - sycytiotrophoblast, cytotrophoblast,
endothelial and Hofbauer cells (p= 0.0001; Fig. 3E). How-
ever, membranous VEGFR-2 expression in the pre-
eclampsia group was found to be significantly down-
regulated than those of ≤ 34 weeks pre-eclamptic placenta
(p = 0.0001) in all the cells. Also, significantly reduced
VEGFR-2 immunoreactivity was found in these cells of
Richa Tripathi, et al.
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Table 4.Assessment of Membranous VEGFR-2 Immunostaining in Third Trimester Pre-Eclamptic Placentae
Cells
≤ 34 wks > 34 wks
Control  group Pre-eclamptic group  Control group  Pre-eclamptic group 
Syncytiotrophoblast ++ ++ +++ +
Cytotrophoblast ++ ++ +++ +
Endothelial cells ++ ++ +++ +
Hofbauer cells ++ ++ +++ +
VEGFR-2, vascular endothelial growth factor receptor-2.
In > 34 weeks - control vs. pre-eclampsia, p= 0.0001.
In ≤34 weeks and > 34 weeks, control vs. control, p= 0.0001;  preeclampsia vs. pre-eclampsia, p= 0.0001.
+, mild reactivity; ++, moderate reactivity; +++, intense reactivity.
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Fig. 2. Receiver Operating Characteristic (ROC) curve analysis of sVEGFR-2 in pre-eclampsia showing the ability of maternal serum sVEGFR-1 to
differentiate pre-eclampsia from normal pregnancies. (A) At  ≤ 34 weeks (AUC = 0.69),  (B) At > 34 weeks (AUC = 0.76). AUC, area under curve.
sVEGFR-2, soluble vascular endothelial growth factor receptor-2 . 
A B
Table 3.Test Performance of Serum sVEGFR-2 in Diagnosing Pre-Eclampsia 
Study group Concentration cut off Sensitivity Specificity LR Area (95% CI)
< 34 wks 6591.0 60% 60% 1.5 0.69
> 34 wks 7350.4 76% 76% 3.1 0.76
LR, likelihood ratio; CI, confidence interval. sVEGFR-2, soluble vascular endothelial growth factor receptor-2.the pre-eclamptic group as compared to the gestationally
matched control patients (p = 0.0001, Table 4, Fig. 3F).
Down-regulation of membranous VEGFR-2 immunoreac-
tivity in pre-eclampsia patients at ≤ 34 weeks and > 34
weeks has been depicted in the bar diagram (Fig. 4).
VEGFR-2 is the major mediator of mitogenic and
angiogenic effects of VEGF. The natural soluble form of
VEGFR-2 has recently been detected in both mouse and
human plasma.
13 In contrast to sVEGFR-1, little is known
about sVEGFR-2. There are clinical studies on sVEGFR-2
as a surrogate biomarker for tumour progression or
survival in melanoma,
19 myelodysplastic,
20 leukaemia
21-23
and pre-eclampsia patients.
24 However, no clear pattern has
yet emerged to indicate the utility of monitoring circulating
sVEGFR-2 in relation to tumour growth, pre-eclampsia
progression and the underlying mechanisms governing the
observed changes.
Ebos et al.
13 detected the soluble form of VEGFR-2 in
conditioned media (CM) obtained from human endothelial
cells, suggesting that endothelial cells are one source of
VEGFR-2 in Pre-Eclampsia
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Fig. 4. Comparison of immunohistochemical H-scores for membranous VEGFR-2 in the cells of control and pre-eclamptic patients at ≤34 and > 34
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Fig. 3.Immunohistochemical staining for VEGFR-2 in normal and pre-eclamptic placenta. (A) Negative control - VEGFR-2 control sections incubated
with IgG non-immune serum (omitted primary antibody) showing syncytiotrophoblast (S) cytotrophoblast (C), Endothelial cells (E) Hofbauer cells (H)
with no staining (Scale bar- 5 µm). (B) Positive control -hCG- Showing placental villi showing intense staining of syncytiotrophoblast (S),
cytotrophoblast (C), Endothelial cells (E) and Hofbauer cells (H) (Scale bar- 5 µm). (C) 28 weeks (≤34 weeks) control placentae showing moderate
VEGFR-2 expression in syncytiotrophoblast (S), cytotrophoblast (C), Endothelial (E), Hofbauer cells (H) (Scale bar - 5µm). (D) 28weeks (≤34 weeks)
pre-eclamptic placentae showing moderate VEGFR-2 expression in syncytiotrophoblast (S), cytotrophoblast (C), Endothelial (E), Hofbauer cells (H)
(Scale bar- 5 µm). (E) 37 weeks (> 34 weeks) control placentae showing intensed VEGFR-2expression in syncytiotrophoblast (S), Endothelial (E) and
Hofbauer cells (H) (Scale bar- 5 µm). (F) 37 weeks (> 34 weeks) pre-eclamptic placentae showing mild VEGFR-2 expression in syncytiotrophoblast
(S), Endothelial (E) and Hofbauer cells (H) (Scale bar- 5 µm). VEGFR-2, vascular endothelial growth factor receptor-2; IgG, immunoglobulin G; hCG,
human Chorio-gonadotropin. 
Expression of membranous VEGFR-2 at ≤34 weeks and > 34 weeksplasma sVEGFR-2. However, the possibility that this
soluble form of VEGFR-2 may be the result of alternative
alternate messenger RNA (mRNA) splicing/or proteolytic
cleavage of the membrane-bound receptor/or by some
other mechanisms was remains to be elucidated.
13 Also, it
is unclear what biological agents could stimulate sVEGFR-2
levels. Till now, only Wen et al.
25 showed sVEGFR-2 has
been shown as a result of mRNA splicing, demonstrating
the alternative splicing of VEGFR-2 mRNA in rat retinal
cells that resulted in truncated form of VEGFR-2 which
encoded a functional form of receptor lacking of a portion
of the intracellular domain. A splice variation for VEGFR-
2 encoding for the VEGFR-2 ectodomain also has not yet
been detected. 
sVEGFR-2 is able to bind VEGF, however, in contrast
to sVEGFR-1 receptor-ligand complex, is heparin-depen-
dent.
26 Maynard et al.
27 suggested that the administration of
adenovirus encoding murine sVEGFR-2 to non-pregnant
rats induces hypertension and proteinuria, showing anti-
angiogenic properties of sVEGFR-2. This biological effect,
however, was not observed in pregnant rats, possibly due to
high levels of unopposed PLGF (which does not bind to
sVEGFR-2) secreted by the placenta in the pregnant state.
Another study supporting the role of sVEGFR-2 as an anti-
angiogenic factor was reported after a local injection of
recombinant sVEGFR-2 which inhibited retinal neo-
vascularisation.
14
So far, there are less data available describing the role of
sVEGFR-2 in pre-eclamptic pregnancy. Masuyama et al.
17
noticed that there was no significant difference in the mean
serum concentration of sVEGFR-2 between patients with
pre-eclampsia and women with normal pregnancies. How-
ever, Chaiworapongsa et al.
24 reported the association of pre-
eclampsia with lower plasma concentrations of sVEGFR-2.
The mean serum concentration of sVEGFR-2 in the
umbilical vein was observed in the same range as in
maternal blood and was reported to be lower in both patients
with pre-eclampsia and those with SGA than in women with
normal pregnancies.
28 Also, it was observed that the
concentration of sVEGFR-2 in plasma [ethylenediaminete-
traacetic acid (EDTA), citrate, or heparin] was not significan-
tly different from that in serum.
13
To date, no study has described the time period of
altered sVEGFR-2 concentrations at different intervals of
third trimester of pre-eclamptic pregnancy. Thus, there is
still not enough evidence to support the view that altered
levels of this angiogenic factor in maternal plasma/serum
of pre-eclamptic women are the consequence or the cause
of a placental insufficiency. Therefore, in this cross-
sectional study, we measured sVEGFR-2 concentration at
the early (≤ 34 weeks) and late (> 34 weeks) onset of pre-
eclampsia, and the result showed that the mean serum
sVEGFR-2 concentration in women with normal pregna-
ncies was similar to that of non-pregnant women which
agrees with the study conducted by Masuyama et al.
17 It
was also noticed that the mean serum concentration of
sVEGFR-2 in control group was significantly higher (p =
0.02) at > 34 weeks (term), compared to ≤ 34 weeks (pre-
term). However, in the early (≤ 34 weeks) and late onset (>
34 weeks) pre-eclampsia group, the sVEGFR-2 concen-
trations were found to be down-regulated at > 34 weeks,
compared to ≤ 34 weeks, but the value was not significant
(p = 0.34). Our findings are partially consistent with the
study conducted by Chaiworapongsa et al.
24 which showed
that patients with early (≤ 34 weeks) and late onset (> 34
weeks) pre-eclamptic group had a much lower median
serum sVEGFR-2 concentration as compared to their
respective controls. However, this finding was unexpected
because pre-eclampsia itself is considered to be an anti-
angiogenic state.
27
Furthermore, our findings suggest the serum levels of
this anti-angiogenic factor for the diagnostic utility of
sVEGFR-2 as a sensitive and specific biomarker for pre-
eclampsia in the late onset of disease. The positive LR of
this marker can increase the probability of having pre-
eclampsia required to alter clinical decision making. The
AUC comparison showed that serum sVEGFR-2 is a
significantly better test to differentiate the late onset (> 34
weeks) with an early onset (≤34 weeks) of pre-eclampsia. 
Soluble VEGFR-1 has a higher affinity for VEGF than
VEGFR-2 and reduces the availability of free VEGF to
bind VEGFR-2.
29 This agrees to the observation that plasma
VEGF concentration in pre-eclampsia is lower than normal
pregnancy. Robinson et al.
30 reported that the reduced
concentrations of free VEGF could interfere with endothe-
lial cell function and survival. Although it was previously
shown that sVEGFR-2 can bind to VEGF,
13 it remains
unknown whether sVEGFR-2, like other soluble receptors
such as sVEGFR-1,
31 can bind and sequester VEGF in
vivo, thereby influencing binding and activation of VEGFRs.
Therefore, it was hypothesised that the lower concentration
of sVEGFR-2 in patients with pre-eclampsia may result
from the low availability of free VEGF to stimulate
VEGFR-2 in endothelial cells.
27,32 Thus, serum sVEGFR-2
concentration could be a surrogate marker of endothelial
cell function in the maternal circulation, since VEGF
signalling through VEGFR-2 is essential for endothelial
cell function and survival.
33
The lower sVEGFR-2 plasma concentrations in patients
with pre-eclampsia, might reflect low regenerative
capacity of endothelial cells.
34 The circulating endothelial
progenitor cells are phenotypically defined by flow
cytometry as cells that express CD34 and VEGFR-2,
35 are
capable of mobilizing to the sites of tissue or endothelial
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with the risk of future death in patients with coronary
artery disease.
36 Alternatively, plasma concentrations of
sVEGFR-2 in patients with pre-eclampsia might reflect
low endothelial cell regenerative capacity. It may be due to
lower number of circulating endothelial progenitor cells
and lower plasma concentrations of sVEGFR-2 in patients
with pre-eclampsia than women with normal pregnan-
cies.
34,37 The numbers of these cells have been proposed to
reflect regenerative capacity of endothelial cells.
36 Consis-
tent with this hypothesis, several lines of evidence suggest
that patient with pre-eclampsia, especially in the early onset
group, or women who delivered a low birth weight neonate
have increased risk of developing cardiovascular disease.
38,39
Hence, this study showed that these pre-eclamptic women
were more susceptible to low regenerative capacity for
endothelial cells, and thus, might be at risk for cardiovas-
cular disease.
Membranous VEGFR-2 is the major positive signal
transducer for both physiological and pathological angio-
genesis. VEGFR-2 knocks-out mice die at E8.0 - 8.5 due
to lack of vasculogenesis which indicates that the VEGFR-
2 signalling is essential for the differentiation of VEGFR-2
positive endothelial precursor cells into vascular endothelial
cells as well as for their proliferation.
40 Takahashi et al.
41
noticed that VEGFR-1 by itself does not generate a strong
signal for vascular permeability activity; it cooperates with
VEGFR-2 to significantly enhance the permeability and is
involved in several diseases. Hence, VEGFR-2 plays a
more important functional role in mediating signalling
events involved in endothelial cell mitogenesis, migration,
survival and vascular permeability.
45 The production and
localization of VEGF and its receptor in trophoblast,
endothelial cells, and Hofbauer cells in placenta villi have
been already investigated.
42-44 A low level of expression for
the membranous form of VEGFR-2 was also observed in
neurons, osteoblasts, pancreatic duct cells, retinal
progenitor cells, and megakaryocytes.
40 VEGFR-2 mRNA
and protein at term are localized almost exclusively to
vascular endothelial cells of the placenta in contrast to
VEGFR-1, which is expressed mainly on trophoblasts.
43,46
Although the membranous isoform of VEGFR-2 was found
to be localized mainly on endothelial cells, a fraction of
hematopoietic cells, also known as circulating endothelial
progenitor cells, also expressed VEGFR-2.
40,47 There is an
evidence to indicate that VEGFR-2 is expressed on
cytotrophoblast stem cells and cells in the proximal columns
of chorionic villi during the first and second trimesters of
preg-nancy
48 showing its fundamental role in cytotro-
phoblast differentiation and survival during placentation.
Several authors observed no significant difference in the
expression of VEGFR-2 mRNA
49 and protein
48 in the
placenta of patients with pre-eclampsia and that of women
with normal pregnancies. However, a study using Western
blot analysis of protein extracted from placentas showed
that a lower expression of sVEGFR-2 was associated with
pre-eclampsia patients as compared to normal patients.
50
Alhough it is unclear what biological agents could stimulate
VEGFR-2 expression, the expression of the membranous
isoform of VEGFR-2 is stimulated by VEGF and TNF-
alpha.
51,52 Conflicting results have been reported regarding
the effect of hypoxia on VEGFR-2 expression: either no
change in umbilical vein
33 decreased in the skin
53 or
increased in the brain
54 depending on the cell type. The
present study depicted the expression of VEGFR-2 in
control and pre-eclamptic placentae at ≤ 34 weeks and at >
34 weeks in syncytiotrophoblast, cytotrophoblast, and
endothelial and Hofbauer cells. This complex pattern of
VEGFR-2 immunoreactivity suggests that it may be
involved not only in the regulation of placental angiogenesis
but also in trophoblast invasion. At > 34 weeks, the
VEGFR-2 immunoreactivity was significantly reduced (p
= 0.0001) in villous trophoblasts, and endothelial cells and
Hofbauer cells of placenta villi in the pre-eclamptic group
as compared to the control group. However, at ≤ 34 weeks,
there was no change found in immunoreactivity of the pre-
eclamptic group as compared to the control one. Therefore,
it is highly likely that the VEGF ligand receptor system,
apart from its endothelial mitogenic effect, must have
additional roles when expressed in non-endothelial cells.
Moreover, abnormal trophoblast invasion and differen-
tiation are associated with pre-eclampsia.
47,50 Pre-eclampsia
is also associated with endothelial dysfunction which is
characterized by an increased endothelial cell-mediated
vasoconstriction, increased vascular permeability and an
increased endothelial-mediated platelet aggregation which
may lead to maternal hypertension, and proteinuria.
55 Since
VEGFR-2 is also expressed in endothelial cells and in
Hofbauer cells, the altered expression of VEGFR-2 in
endothelial cells and Hofbauer cells in pre-eclamptic
placentae may interfere with VEGF mediated actions on
these cells. This may affect normal fusion of angiogenic
cell cords and organization of vascular capillaries. It
suggests that VEGFR-2 is a key factor associated with pre-
eclamptic pregnancies and its varying expression may alter
VEGF mediated function on trophoblast, endothelial cells
and Hofbauer cells.
Our results may be explained by VEGF-mediated recep-
tor down-regulation from the cell surface, as membranous
VEGFR-2 is in direct contact with maternal blood in inter-
villous space, which in turn leads to reduced sVEGFR-2
levels in serum in an autocrine manner, thus implying that
expression levels of VEGFR-2 and its soluble forms are
linked together. These results suggest that the decrease of
VEGFR-2 in Pre-Eclampsia
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portional to the progression of pre-eclampsia during pre-
gnancy, indicating a potential role of these proteins in the
pathogenesis of this disorder. VEGF binding and activation
of the VEGFR-2 may lead to down-regulation of the
receptor from the cell surface
56,57 which, in turn may lead to
correlative decreases in sVEGFR-2 production. However,
it remains unknown whether the sVEGFR-2 is a product of
ectodomain cleavage from cell-surface VEGFR-2 or a
product of alternative mRNA splice variation. 
Our findings strongly suggest the clinical utility of
sVEGFR-2 and membranous VEGFR-2 in pregnancies
complicated by pre-eclampsia patients. This information of
significant down-regulation of serum sVEGFR-2 levels
and membranous VEGFR-2 expression in pre-eclampsia
patients may be used as a strategy for mapping out the
management plans to pre-eclamptic patients. Furthermore,
this may lead to better insights into the diagnosis and treat-
ment of pre-clampsia by angiogenic and anti-angiogenic
therapy, and in turn may improve further understanding
and utilization of sVEGFR-2 as a potential biomarker for
monitoring pre-eclampsia progression.
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